Solid Biosciences Inc (SLDB) - Biznesning o‘zini qoplash muddati

Solid Biosciences Inc (SLDB) korporativ emblemasi va logotipi

Solid Biosciences Inc. (SLDB) strategiyasi o'z patentlari ustidan to'liq nazoratni saqlagan holda, klinik sinovlarni tashqi pudratchilarga topshirishga asoslangan. Hozirda -3.90 darajasida bo'lgan ushbu P/E koeffitsiyenti grafigi, muvaffaqiyatning davlat moliyalashtirishiga bog'liqligi va yangi dori vositalarining xavfsizligiga tegishli ma'lumotlarni to'ldiradi. Solid Biosciences Inc. (SLDB) hozirda salbiy pul oqimi tufayli grantlar va avanslarga tayangan holda, kam uchraydigan patologiyalar uchun gen terapiyalarini ishlab chiqmoqda.

solidbio.com - SLDB Narx-foyda koeffitsiyenti (davr: 04.07.2022 - 12.11.2026)

Solid Bio (SLDB) boʻyicha keng qamrovli koʻrsatkichlar kesimi va tahlil

- kotirovkalar va tahlilchilar prognozi:
Narx grafigi solidbio.com|SLDB - Tahlilchilar konsensus prognozi
- bozor kapitallashuvi ko'rsatkichlari:
Bozor kapitallashuvi Solid Biosciences Inc.|SLDB - Korxona qiymati
- balans kapitallashuvi bo'yicha ma'lumotlar:
Bitta aksiya hisobiga xususiy kapital Solid Biosciences|SLDB - Kompaniyaning sof aktivlari|Balans qiymatiga nisbatan bozor qiymati solidbio.com|SLDB - Kompaniyaning umumiy aktivlari
- qarzlar va to'lov qobiliyati haqida ma'lumot:
Qarzning xususiy kapitalga nisbati Solid Biosciences Inc.|SLDB - Uzoq muddatli qarzning kapitalga nisbati|Qisqa muddatli qarzning kapitalga koeffitsiyenti Solid Corp|SLDB - Kompaniya qarzlari|Balans qiymatiga qarzlar Solid Biosciences Inc.|SLDB - Kompaniyaning uzoq muddatli qarzi|Qisqa muddatli qarz hajmi Solid Biosciences|Tezkor likvidlik ko‘rsatkichi solidbio.com
- moliyaviy natijalar va qiymat multiplikatorlari tafsilotlari:
SLDB - Sof foyda|Kompaniya foydasi prognozi Solid Biosciences Inc.|SLDB - P/E multiplikatori|Prognoz qilingan narx-foyda nisbati Solid Biosciences Inc|SLDB - Narxning foydaga va o‘sish sur’atiga nisbati|Korxona qiymatining amortizatsiyadan oldingi operatsion foydaga nisbati Solid Biosciences Inc.|SLDB - EBITDA operatsion foydasi|So'nggi 12 oy davomida bir aksiya uchun sof foyda Solid Biosciences|SLDB - Bir aksiya uchun sof foyda (EPS TTM)|So'nggi o'n ikki oy davomida yillik hisobda bir aksiya uchun foyda o'sishi solidbio.com|SLDB - Joriy yilda bir aksiya uchun foyda o'sishi|Keyingi yil uchun bir aksiya uchun foyda o'sishining konsensus prognozi Solid Biosciences Inc.
Kompaniyaning har tomonlama tahlili:SLDB (solidbio.com)
Solid Biosciences Inc. brendining mahsuloti

P/E koeffitsienti bozor qiymatining sof foydaga nisbatini hisoblagan holda investitsiyalarning qoplanish muddatini o'lchaydi. Kompaniyaning P/E tebranishlarini tahlil qilish orqali investor daromadlar pasayishi davrida "qiymat tuzog'i" xavfini aniqlashi mumkin. Solid Biosciences Inc. (SLDB) uchun ushbu metrika juda muhimdir, chunki ishlab chiqarishni uchinchi tomon pudratchilariga topshirish marjalarning hamkorlarga bog'liqligini yuzaga keltiradi. Ushbu ko'rsatkichning barqarorligi R&D modelining hayotiy ekanligini va biznesning chidamliligini tasdiqlaydi.

Raqobatdosh kompaniyalar tahlili

Narxning foydaga nisbati TEM|P/E multiplikatori QGEN|Biznesning o‘zini qoplash muddati Ionis Pharmaceuticals, Inc.|P/E multiplikatori RGEN (Repligen Corp.)|RNA: Narx-foyda multiplikatori|CRSP: Narx-foyda koeffitsiyenti|Kompaniya qiymatining sof foydaga nisbati WGS (genedx.com)|RARE: P/E multiplikatori|BEAM (Beam Therapeutics Inc) - Narxning foydaga nisbati|SRPT (Sarepta Therapeutics Inc) - P/E multiplikatori|Twist Bioscience Corp (TWST) - Biznesning o‘zini qoplash muddati|Narxning foydaga nisbati 10x Genomics, Inc. (TXG)|NTLA - Kapitalizatsiyaning foydaga nisbati|Narxning foydaga nisbati Stoke Therapeutics, Inc. STOK|Biznesning o‘zini qoplash muddati BioLife Solutions Inc (BLFS)|Wave Life Sciences Corp - P/E multiplikatori|Maze Therapeutics Corp (MAZE) - Narx-foyda koeffitsiyenti|SION: P/E multiplikatori|PRME - Biznesning o‘zini qoplash muddati|TSHA (Taysha Gene Therapies, Inc.) - P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati uniQure NV QURE|Narxning foydaga nisbati MeiraGTx PLC (MGTX)|REGENXBIO Corp - Narx-foyda multiplikatori|P/E multiplikatori OCGN (Ocugen, Inc.)|PACB - Narx-foyda koeffitsiyenti|Benitec Biopharma - P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati Design Therapeutics Inc|Rocket Pharmaceuticals Inc (RCKT) - Narxning foydaga nisbati|FDMT - Biznesning o‘zini qoplash muddati|Narx-foyda koeffitsiyenti LXEO|KRRO: Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori EDIT|Biznesning o‘zini qoplash muddati Silence Therapeutics PLC|Narxning foydaga nisbati ProQR Therapeutics PRQR|CDXS: Narx-foyda multiplikatori|Sangamo Therapeutics - P/E multiplikatori|Nautilus Biotechnology (NAUT) - Narx-foyda koeffitsiyenti|MGX (Metagenomi) - Narx-foyda koeffitsiyenti|DTIL - Biznesning o‘zini qoplash muddati|Narxning foydaga nisbati Generation Bio Co|Boundless Bio Inc (BOLD) - Biznesning o‘zini qoplash muddati|Narxning foydaga nisbati Exicure, Inc. (XCUR)|Narxning foydaga nisbati IMNN (imunon.com)|P/E multiplikatori PHIO (Phio Pharmaceuticals Corp.)|MBIO: Narx-foyda multiplikatori|TransCode - P/E multiplikatori|BNGO: Narxning foydaga nisbati|APDN: P/E multiplikatori|Narx-foyda multiplikatori BLUE|Narxning foydaga nisbati ImmunoPrecise Antibodies Ltd|Narx-foyda multiplikatori OMGA (Omega Therapeutics Inc)|P/E multiplikatori OMIC|P/E multiplikatori Regulus (RGLS)|Narxning foydaga nisbati Syros Pharmaceuticals SYRS|Biznesning o‘zini qoplash muddati telesisbio.com (TBIO)|TCON - Narxning foydaga nisbati|Kapitalizatsiyaning foydaga nisbati Unity Biotechnology Inc.